MediciNova, Inc. (MNOV)
MNOV Stock Price Chart
Explore MediciNova, Inc. interactive price chart. Choose custom timeframes to analyze MNOV price movements and trends.
MNOV Company Profile
Discover essential business fundamentals and corporate details for MediciNova, Inc. (MNOV) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
8 Dec 2006
Employees
13.00
Website
https://www.medicinova.comCEO
Yuichi Iwaki
Description
MediciNova, Inc. is a biopharmaceutical firm dedicated to discovering and advancing innovative small molecule therapies for severe illnesses where current treatments are insufficient within the United States. Its robust development pipeline features MN-166 (ibudilast), an oral agent with both anti-inflammatory and neuroprotective properties, currently being investigated for a range of neurological conditions. These include primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and various forms of substance dependence and addiction. The company's portfolio also comprises MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist aimed at treating acute asthma attacks; MN-001 (tipelukast), an orally available small molecule designed for fibrotic disorders like nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent intended for solid tumor oncology. MediciNova has established strategic partnerships with companies such as Kissei Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Angiogene Pharmaceuticals Ltd., and Meiji Seika Kaisha Ltd. Established in 2000, the company's headquarters are situated in La Jolla, California.
MNOV Financial Timeline
Browse a chronological timeline of MediciNova, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Aug 2026
EPS estimate is -$0.06, while revenue estimate is $75.00k.
Earnings released on 15 May 2026
EPS came in at -$0.05 surpassing the estimated -$0.06 by +16.67%, while revenue for the quarter reached $186.98k , meeting expectations.
Earnings released on 20 Feb 2026
EPS came in at -$0.05 surpassing the estimated -$0.10 by +47.37%, while revenue for the quarter reached $151.00k , missing expectations by -0.49%.
Earnings released on 13 Nov 2025
EPS came in at -$0.06 surpassing the estimated -$0.08 by +25.00%, while revenue for the quarter reached $61.50k , missing expectations by -50.13%.
Earnings released on 14 Aug 2025
EPS came in at -$0.07 matching the estimated -$0.07, while revenue for the quarter reached $134.60k .
Earnings released on 14 May 2025
EPS came in at -$0.06 surpassing the estimated -$0.14 by +57.14%.
Earnings released on 19 Feb 2025
EPS came in at -$0.06 matching the estimated -$0.06.
Earnings released on 14 Nov 2024
EPS came in at -$0.06 matching the estimated -$0.06.
Earnings released on 8 Aug 2024
EPS came in at -$0.05 surpassing the estimated -$0.06 by +16.67%.
Earnings released on 10 May 2024
EPS came in at -$0.06 falling short of the estimated -$0.05 by -20.00%.
Earnings released on 15 Feb 2024
EPS came in at -$0.04 surpassing the estimated -$0.08 by +50.00%.
Earnings released on 9 Nov 2023
EPS came in at -$0.01 surpassing the estimated -$0.08 by +87.50%, while revenue for the quarter reached $1.00m .
Earnings released on 10 Aug 2023
EPS came in at -$0.06 surpassing the estimated -$0.07 by +14.29%.
Earnings released on 11 May 2023
EPS came in at -$0.06 surpassing the estimated -$0.07 by +14.29%.
Earnings released on 16 Feb 2023
EPS came in at -$0.06 surpassing the estimated -$0.09 by +29.41%.
Earnings released on 10 Nov 2022
EPS came in at -$0.07 surpassing the estimated -$0.09 by +22.22%.
Earnings released on 11 Aug 2022
EPS came in at -$0.08 matching the estimated -$0.08.
Earnings released on 12 May 2022
EPS came in at -$0.07 surpassing the estimated -$0.09 by +22.22%.
Earnings released on 17 Feb 2022
EPS came in at -$0.04 surpassing the estimated -$0.09 by +55.56%.
Earnings released on 12 Nov 2021
EPS came in at -$0.07 surpassing the estimated -$0.09 by +22.22%, while revenue for the quarter reached $37.50k , missing expectations by -18.18%.
Earnings released on 12 Aug 2021
EPS came in at -$0.09 matching the estimated -$0.09.
MNOV Stock Performance
Access detailed MNOV performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
